ZZZiqi Zhuang

Ziqi Zhuang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ziqi Zhuang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Liu

    State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen China

    2 shared publications
  • Peiyu Wang

    State Key Laboratory of Vaccines for Infectious Diseases Center for Molecular Imaging and Translational Medicine Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research School of Public Health Xiamen University Xiamen China

    2 shared publications
  • Changhong Li

    State Key Laboratory of Cellular Stress Biology Innovation Center for Cell Biology School of Life Sciences Xiamen University Xiamen 361102 China

    1 shared publication
  • Chao Liu

    State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China

    1 shared publication
  • Chengchao Chu

    Xiamen University

    1 shared publication
  • Chenhao Zhang

    State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China

    1 shared publication

Latest Publications

  • Open Access

    Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity

    by Shuo Li, Peiyu Wang, Zhenyu Wu, Qianwen Mu, Renwu Zhou, Nina Liu, Yue Xi, Xiaoyu An, Yan Li, Di Sun, et al.

    Cancer immunotherapy remains limited by insufficient antigen presentation and immunosuppressive tumor microenvironment. Here, we present a vaccine strategy based on cold atmospheric plasma (CAP)–engineered tumor cell–derived immune reprogramming nanovesicles (CAPTURE) that integrates spatiotemporal sequential immunization to potentiate antitumor immunity. CAPTURE is engineered from tumor cells pretreated with CAP, which up-regulates major histocompatibility complex class I expression via p62-mediated autophagy to promote full-spectrum epitope antigen presentation, and surface-functionalized anti-CD28 (αCD28) on CAPTURE provides costimulatory signals to directly activate T cells through αCD28-CD28, bypassing B7-CTLA-4–mediated T cell inhibition. Under spatiotemporal sequential immunity, CAPTURE exhibits homologous tumor targeting and lymph node accumulation, enhancing antigen presentation for CD8 + T cell activation and tumor immunogenic remodeling. In mouse models, CAPTURE achieved near-complete tumor suppression, driven by amplified cytotoxic T cell responses, increased T cell clonal diversity, and CXCR3-mediated tumor infiltration. This study presents a universal biomimetic nanovaccine strategy that can reshape both T cells’ immunity and tumor cells’ immunogenicity, induce broad-spectrum immune responses to overcome immune evasion, and offer unique insights and innovative technologies for precision cancer immunotherapy.


  • A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy

    by Jinyong Lin, Dong Li, Changhong Li, Ziqi Zhuang, Chengchao Chu, Kostya (Ken) Ostrikov, Erik W. Thompson, Gang Liu, Peiyu Wang

    The multi-modal therapy has superior anti-tumor efficacy to the uni-modal using nanoparticles inducing reactive oxygen species (ROS). The multi-component nature of cold atmospheric plasma (CAP) enables multi-modal excitation with a single treatment.